dpp4 inhibitor screening assay kit  (Danaher Inc)

Journal: Clinical & Translational Oncology

Article Title: Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer

doi: 10.1007/s12094-023-03187-5

Figure Lengend Snippet: Anagliptin inhibits tumor-associated macrophages (TAMs) formation in the tumor microenvironment. a, b , The percentages of macrophages (CD11b + F4/80 + ), natural killer (NK) (NK1.1 + CD3 − ) cells, CD4 + T (CD3 + CD4 + CD8 − ) cells, and CD8 + T (CD3 + CD8 + CD4 − ) cells in primary tumors on day 18 are determined by flow cytometry. ***, P < 0.01. c, d , Representative immunofluorescence images showing CD206 (green), F4/80 (red), and nucleus (blue) staining of the primary tumors from all groups on day 18. *, P < 0.05; **, P < 0.01. e , The expression levels of dipeptidyl peptidase 4 (DPP4), F4/80, and CD206 in primary tumors on day 18 from all groups are analyzed by western blotting. f , The expression levels of M1 cytokines (nitric oxide synthase [iNOS], tumor necrosis factor-α [TNF-α]) and M2 cytokines (interleukin 10 [IL-10], arginase-1 [ARG-1]) in primary tumors on day 18 from all groups are analyzed by real-time polymerase chain reaction. *, P < 0.05; **, P < 0.01

Article Snippet: Antibodies against DPP4 (ab28340, Abcam), F4/80 (28463-1-AP, Proteintech), CD206 (18704-1-AP, Proteintech), p44/42 MAPK (Erk1/2) (137F5) rabbit mAb (4695, Cell Signaling Technology), Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (9101, Cell Signaling Technology), signal transducer and activator of transcription 6 (STAT6) (ab32520, Abcam), and Phospho-STAT6 (phospho Y641) (ab263947, Abcam) were used at a dilution of 1:2000.

Techniques: Flow Cytometry, Immunofluorescence, Staining, Expressing, Western Blot, Real-time Polymerase Chain Reaction